针对性治疗的进步:解决B细胞淋巴细胞恶性瘤中对BTK抑制的抵抗
Andres Bravo-Gonzalez1, Maryam Alasfour2, Deborah Soong2
1London School of Hygiene and Tropical Medicine, Bogotá 110221, Colombia.
Cancers
|October 26, 2024
概括
对布鲁顿的抵抗力
科学领域:
- 血液瘤学 血液瘤学
- 癌症的分子机制
背景情况:
- 乙细胞淋巴性恶性瘤是不同的血液癌症.
- 布鲁顿的氨酸激酶 (BTK) 抑制剂是FDA批准的几种亚型的治疗方法.
- 联BTK抑制剂如Ibrutinib向C481残留物,但可以出现耐药性.
研究的目的:
- 审查对共价和非共价BTK抑制剂耐药性的分子和遗传机制.
- 讨论新兴的治疗策略,包括BTK降解剂,以克服耐药性.
主要方法:
- 对BTK抑制剂耐药性的现有文献的综述.
- 分析分子途径和遗传突变,从而产生抗药性.
- 讨论新的治疗方法,如蛋白质分解向嵌合体 (PROTACs).
主要成果:
- 对共价BTK抑制剂的耐药性可能来自BTK结合部位 (C481S) 或其他部位的突变,以及PLCγ2.的突变.
- 非共价BTK抑制剂,如Pirtobrutinib,对野生型和C481S突变BTK有效.
- 降解BTK的降解剂代表了一种有前途的新疗法,用于克服耐药性.
结论:
- 了解抵抗机制对于开发有效的BTK向疗法至关重要.
- 新兴的策略,包括非共价抑制剂和BTK降解剂,为治疗抗性B细胞恶性瘤提供了新的途径.
- 对抗性和新型治疗方法的持续研究推动了对这些癌症的治疗方法的追求.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy
486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cytotoxic T Cells-mediated Immune Response
853
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
853


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)